COVID-19 Pandemic


Current status of authorisations for combating COVID-19

Applications  received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.

Empfehlung des Bundesrates: Bleiben Sie zu Hause, insbesondere, wenn Sie alt oder krank sind

Information on the current situation in Switzerland

Information for health professionnals, FAQs, recommendations for travellers.

 
Official information page
Covid-FAQ

FAQ on the COVID-19 vaccines

On this page you’ll find answers to frequently asked questions about mRNA vaccines.


All about the vaccines - briefly and concisely explained

Vaccines: Rapid solution for new diseases?

Swismedic - The way a vaccination works

How an mRNA vaccine works

How a vector vaccine works?

How a protein vaccine works

How is the safety of vaccines monitored?


Communication regarding COVID-19

01.06.2023

Out-of-Stock – COVID-19 – Authorisations for the temporary import and distribution of human medicines – Update

Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3

11.04.2023

Swissmedic approves bivalent Pfizer Ltd. COVID-19 Original / Omicron BA 4-5 booster dose for adults aged 12 and over

Bivalent Original / Omicron BA.4-5 mRNA vaccine (tozinameran / famtozinameran) approved

27.03.2023

Comirnaty® COVID-10 vaccines from Pfizer AG: authorisation without special conditions approved

Three formulations (authorisation nos. 68225 and 68710, with 30 and 10 μg/dose) authorised for five years

08.03.2023

Swissmedic issues unlimited authorisation* for booster dose of Moderna's bivalent COVID-19 Original / Omicron BA.4-5 vaccine

Spikevax bivalent Original / Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over

24.02.2023

Reports of suspected adverse reactions to COVID-19 vaccines

16,855 reports of suspected adverse vaccination reactions evaluated

23.01.2023

Validity of GMP certificates during the COVID-19 pandemic

Update of the validity period of EMA GMP certificates

25.11.2022

Reports of suspected adverse reactions to COVID-19 vaccines

16,212 reports of suspected adverse vaccination reactions evaluated

18.11.2022

Moderna applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine

Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222)
https://www.swissmedic.ch/content/swissmedic/en/home/news/coronavirus-covid-19.html